MDxHealth (MDXH) Stock Overview
A commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MDXH Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
MDxHealth SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.44 |
| 52 Week High | US$5.33 |
| 52 Week Low | US$0.40 |
| Beta | -501440.85 |
| 1 Month Change | -7.24% |
| 3 Month Change | -78.12% |
| 1 Year Change | -82.25% |
| 3 Year Change | -87.37% |
| 5 Year Change | -97.05% |
| Change since IPO | -99.49% |
Recent News & Updates
MDXH: Resolve Exit And Medicare Review Will Reset Prostate Cancer Focus
Analysts have sharply reduced their price targets on MDxHealth, with cuts such as $7 to $1.50, $9 to $5, and $7 to $4, reflecting weaker Q1 revenue, lowered guidance, and the exit of the Resolve UTI business following reimbursement and recoupment disputes. Analyst Commentary Recent research on MDxHealth highlights a mix of caution and optimism, with analysts reacting to weaker Q1 revenue, revised guidance, and the exit of the Resolve UTI business.MDXH: Resolve Exit And Medicare Review Will Refocus On Prostate Cancer
Analysts have cut their fair value estimate for MDxHealth from $9.00 to $5.00, citing reduced revenue growth assumptions, a higher discount rate, and a lower future P/E multiple after the Q1 miss, the Resolve exit, and reimbursement uncertainties. Analyst Commentary Recent Street research on MDxHealth reflects a reset in expectations after the Q1 shortfall, the Resolve exit, and reimbursement questions, but also highlights areas where analysts still see potential for execution and valuation recovery.
MDXH: Future Upside Will Depend On Resolving The 10.4m Medicare Dispute
Analysts have reduced their fair value estimate for MDxHealth from $4.20 to $1.00 following weak Q1 results, lower revenue guidance, the discontinuation of the Resolve UTI test, and uncertainty surrounding a $10.4m Medicare recoupment notice and the closure of the related Texas lab. Analyst Commentary on MDxHealth Recent Street research on MDxHealth highlights a clear shift toward caution, with several bearish analysts cutting price targets and reassessing the risk profile after the weak Q1 update, reduced revenue guidance, the Medicare recoupment notice of $10.4m, and the decision to close the Texas lab tied to the Resolve UTI test.Recent updates
MDXH: Resolve Exit And Medicare Review Will Reset Prostate Cancer Focus
Analysts have sharply reduced their price targets on MDxHealth, with cuts such as $7 to $1.50, $9 to $5, and $7 to $4, reflecting weaker Q1 revenue, lowered guidance, and the exit of the Resolve UTI business following reimbursement and recoupment disputes. Analyst Commentary Recent research on MDxHealth highlights a mix of caution and optimism, with analysts reacting to weaker Q1 revenue, revised guidance, and the exit of the Resolve UTI business.MDXH: Resolve Exit And Medicare Review Will Refocus On Prostate Cancer
Analysts have cut their fair value estimate for MDxHealth from $9.00 to $5.00, citing reduced revenue growth assumptions, a higher discount rate, and a lower future P/E multiple after the Q1 miss, the Resolve exit, and reimbursement uncertainties. Analyst Commentary Recent Street research on MDxHealth reflects a reset in expectations after the Q1 shortfall, the Resolve exit, and reimbursement questions, but also highlights areas where analysts still see potential for execution and valuation recovery.MDXH: Future Upside Will Depend On Resolving The 10.4m Medicare Dispute
Analysts have reduced their fair value estimate for MDxHealth from $4.20 to $1.00 following weak Q1 results, lower revenue guidance, the discontinuation of the Resolve UTI test, and uncertainty surrounding a $10.4m Medicare recoupment notice and the closure of the related Texas lab. Analyst Commentary on MDxHealth Recent Street research on MDxHealth highlights a clear shift toward caution, with several bearish analysts cutting price targets and reassessing the risk profile after the weak Q1 update, reduced revenue guidance, the Medicare recoupment notice of $10.4m, and the decision to close the Texas lab tied to the Resolve UTI test.MDxHealth SA (NASDAQ:MDXH) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
MDxHealth SA ( NASDAQ:MDXH ) shareholders won't be pleased to see that the share price has had a very rough month...Shareholder Returns
| MDXH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.5% | -2.4% | 2.4% |
| 1Y | -82.2% | 31.5% | 19.6% |
Return vs Industry: MDXH underperformed the US Biotechs industry which returned 31.5% over the past year.
Return vs Market: MDXH underperformed the US Market which returned 19.6% over the past year.
Price Volatility
| MDXH volatility | |
|---|---|
| MDXH Average Weekly Movement | 18.3% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MDXH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MDXH's weekly volatility has increased from 12% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 364 | Mike McGarrity | mdxhealth.com |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company’s testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient’s infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment.
MDxHealth SA Fundamentals Summary
| MDXH fundamental statistics | |
|---|---|
| Market cap | US$23.37m |
| Earnings (TTM) | -US$33.18m |
| Revenue (TTM) | US$110.97m |
Is MDXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDXH income statement (TTM) | |
|---|---|
| Revenue | US$110.97m |
| Cost of Revenue | US$40.23m |
| Gross Profit | US$70.74m |
| Other Expenses | US$103.92m |
| Earnings | -US$33.18m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 13, 2026
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 63.75% |
| Net Profit Margin | -29.90% |
| Debt/Equity Ratio | -474.3% |
How did MDXH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/04 22:22 |
| End of Day Share Price | 2026/08/04 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MDxHealth SA is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ruzic-Gauthier | Berenberg |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |